Patents Assigned to ConjuChem, Inc.
-
Patent number: 7144854Abstract: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.Type: GrantFiled: September 7, 2000Date of Patent: December 5, 2006Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Michele Rasamoelisolo, Karen Thibaudeau, Xicai Huang, Richard Beliveau
-
Patent number: 7112567Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.Type: GrantFiled: February 15, 2002Date of Patent: September 26, 2006Assignee: ConjuChem Inc.Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Léger, Martin Robitaille, Karen Thibaudeau, Julie Carette
-
Patent number: 7090851Abstract: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.Type: GrantFiled: September 7, 2000Date of Patent: August 15, 2006Assignee: ConjuChem Inc.Inventors: Dominique P. Bridon, Robert R. Dufresne, Nissab Boudjellab, Martin Robitaille, Peter G. Milner
-
Publication number: 20060135426Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: December 14, 2005Publication date: June 22, 2006Applicant: CONJUCHEM, INC.Inventors: Dominique Bridon, Benoit L' Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20060058235Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: August 30, 2005Publication date: March 16, 2006Applicant: CONJUCHEM, INC.Inventors: Dominique Bridon, Benoit L'Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20060009377Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: June 29, 2005Publication date: January 12, 2006Applicant: CONJUCHEM, INC.Inventors: Dominique Bridon, Benoit L'Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge Pierre
-
Publication number: 20050267293Abstract: The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate.Type: ApplicationFiled: April 22, 2005Publication date: December 1, 2005Applicant: ConjuChem, Inc.Inventors: Nathalie Bousquet-Gagnon, Omar Quraishi, Dominique Bridon
-
Publication number: 20050187159Abstract: A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.Type: ApplicationFiled: February 25, 2005Publication date: August 25, 2005Applicant: ConjuChem, Inc.Inventors: Dominique Bridon, Alan Ezrin, Peter Milner, Darren Holmes, Karen Thibaudeau
-
Publication number: 20050176643Abstract: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.Type: ApplicationFiled: February 25, 2005Publication date: August 11, 2005Applicant: ConjuChem, Inc.Inventors: Dominique Bridon, Roger Leger, Xicai Huang, Karen Thibaudeau, Martin Robitaille, Peter Milner
-
Publication number: 20050176641Abstract: This invention relates to long lasting natriuretic peptide (NP) derivatives. The NP derivative has a NP peptide and a reactive entity coupled to the NP peptide. The reactive entity is able to covalently bond with a functionality on a blood component. In particular, this invention relates to NP derivatives having an extended in vivo half-life, and method for the treatment of cardiovascular diseases and disorders such as acute decompensated congestive heart failure (CHF) and chronic CHF.Type: ApplicationFiled: January 21, 2005Publication date: August 11, 2005Applicant: CONJUCHEM, INC.Inventors: Peter Bakis, Dominique Bridon, Julie Carette, France Leclaire, Roger Leger, Martin Robitaille
-
Patent number: 6887849Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: November 4, 2002Date of Patent: May 3, 2005Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Patent number: 6887470Abstract: A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.Type: GrantFiled: September 7, 2000Date of Patent: May 3, 2005Assignee: Conjuchem, Inc.Inventors: Dominique P. Bridon, Alan M. Ezrin, Peter G. Milner, Darren L. Holmes, Karen Thibaudeau
-
Publication number: 20050070475Abstract: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.Type: ApplicationFiled: September 24, 2004Publication date: March 31, 2005Applicant: ConjuChem, Inc.Inventors: Dominique Bridon, Robert Dufresne, Nissab Boudjellab, Martin Robitaille, Peter Milner
-
Publication number: 20050037974Abstract: Methods and compositions are provided for identifying compounds having affinity or complementarity to a target molecule. Compounds according to the invention may be described by the formula E-Ca—R—Cb-A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, Ca and Cb are connector groups between E and R and between R and A, respectively, and A is a group having an affinity for human serum albumin, wherein affinity group A comprises a sequence of amino acid residues —O1—O2—X1—X2—B in which the amino acid residues are independently selected from the group of all twenty naturally occurring amino acids. Compounds according to the invention may be used for labeling the target molecule, particularly where the target molecule is naturally found in a complex mixture, such as a physiological fluid, like blood. By affinity labeling in vivo, the lifetime of physiologically active entities can be greatly enhanced by becoming bound to long-lived blood components.Type: ApplicationFiled: September 2, 2004Publication date: February 17, 2005Applicant: ConjuChem, Inc.Inventors: Alexander Krantz, Wolin Huang, Arthur Hanel, Darren Holmes, Dominique Bridon
-
Patent number: 6849714Abstract: A method of synthesizing a modified therapeutic peptide capable of forming a peptidase-stabilized therapeutic peptide conjugate, the peptide having between 3 and 50 amino acids, is k. In a first step of the method, a therapeutic peptide having a carboxy terminal amino acid and amino terminal amino acid is synthesized. In a second step, pairs of cysteine residues present in the therapeutic peptide are sequentially and selectively oxidized to form disulfide bridges in the therapeutic peptide. In a third step, a protecting group is attached to remaining cysteine residues that do not form disulfide bridges in the therapeutic peptide. Finally, the peptide is coupled to a reactive group capable of reacting with amino groups, hydroxyl groups or thiol groups on a blood component to form a covalent bond therewith.Type: GrantFiled: May 17, 2000Date of Patent: February 1, 2005Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Alan M. Ezrin, Peter G. Milner, Darren L. Holmes, Karen Thibaudeau
-
Patent number: 6821949Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: November 4, 2002Date of Patent: November 23, 2004Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20040156859Abstract: Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosupressants, anti-infective and anti-cancer agents.Type: ApplicationFiled: January 12, 2004Publication date: August 12, 2004Applicant: CONJUCHEM, INC.Inventors: Alan M. Ezrin, Angelica Fleser, Martin Robitaille, Peter G. Milner, Dominique P. Bridon
-
Publication number: 20040138100Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: November 25, 2003Publication date: July 15, 2004Applicant: CONJUCHEM, INC.Inventors: Dominique Bridon, Benoit L' Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Publication number: 20040127398Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: ApplicationFiled: November 25, 2003Publication date: July 1, 2004Applicant: CONJUCHEM, INC.Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Patent number: 6706892Abstract: Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosupressants, anti-infective and anti-cancer agents.Type: GrantFiled: September 6, 2000Date of Patent: March 16, 2004Assignee: Conjuchem, Inc.Inventors: Alan M. Ezrin, Angelica Fleser, Martin Robitaille, Peter G. Milner, Dominique P. Bridon